Pfizer (PFE) reported $17.56 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of ...
In the global biosimilars market, the sands are shifting underfoot. It's time for all stakeholders to re-examine the present environment and re-set expectations for the future. From the creation of a ...
Pfizer is to launch its biosimilar of Johnson & Johnson's blockbuster inflammatory diseases drug Remicade next month in the US. This is only the second biosimilar drug to be launched in the US, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results